TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis

Blood

Volumn 95, Issue 12, 2000, Pages 3716-3724

  Zamai, Loris ^a   Secchiero, Paola ^b   Pierpaoli, Sabina ^b   Bassini, Alessandra ^b   Papa, Stefano ^b   Alnemri, Emad S ^b   Guidotti, Lia ^b   Vitale, Marco ^b   Zauli, Giorgio ^b  

^a UNIVERSITY OF URBINO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYTOKINE; ERYTHROPOIETIN; GLYCOPHORIN A; INTERLEUKIN 3; REGULATOR PROTEIN; STEM CELL FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL LINEAGE; CELL SURVIVAL; CONTROLLED STUDY; ERYTHROBLAST; ERYTHROPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ADULT; ANTIGENS, CD; ANTIGENS, CD15; ANTIGENS, CD34; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BONE MARROW CELLS; CELL SURVIVAL; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; ERYTHROPOIESIS; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034659824     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Earnshaw WC. Apoptosis: a cellular poison cupboard. Nature. 1999;397:337.
2. Park JR. Cytokine regulation of apoptosis in hematopoietic precursor cells. Curr Opin Hematol. 1996;3:191.
3. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interleron gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85:3183.
4. Nagafuji K, Takenaka K, Shibuya T, Harada M, Niho Y. Fas antigen (CD95) and hematopoietic progenitor cells. Leuk Lymphoma. 1996;24:43.
5. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11:255.
6. Niho Y, Asano Y. Fas/Fas ligand and hematopoietic progenitor cells. Curr Opin Hematol. 1998;5: 163.
7. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol. 1995;91:245.
8. Dai CH, Price JO, Brunner T, Krantz SB. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood. 1998;91:1235.
9. De Maria R, Testa U, Luchetti L, et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood. 1999;93:796.
10. Takenaka K, Nagafuji K, Harada M, et al. In vitro expansion of hematopoietic progenitor cells induces functional expression of Fas antigen (CD95). Blood. 1996;88:2871.
11. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673.
12. Snell V, Clodi K, Zhao S, et al. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol. 1997; 99:618.
13. Mariani SM, Matiba B, Armandola EA, Krammer PH. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol. 1997;137:221.
14. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol. 1998;28:973.
15. Jeremias I, Herr I, Boehler T, Debatin KM. TRAIL/ Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol. 1998;28:143.
16. Herr I, Wilhelm D, Bohler T, Angel P, Debatin KM. JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-alpha. Int J Cancer. 1999;80:417.
17. Martinez-Lorenzo MJ, Anel A, Gamen S, et al. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol. 1999;163:1274.
18. Bretz JD, Rymaszewski M, Arscott PL, et al. TRAIL death pathway expression and induction in thyroid follicular cells. J Biol Chem. 1999;274: 23627.
19. Walczack H, Degli Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997;16:5386.
20. Rieger J, Ohgaki H, Kleihues P, Weller P. Human astrocytic brain tumors express AP02L/TRAIL. Acta Neuropathol. 1999;97:1.
21. MacFarlane M, Manzoor A, Srinivasula SM, Femandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem. 1997;41:25417.
22. Zamai, L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998;188:2375.
23. Zauli G, Vitale M, Falcieri E, et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood. 1997;90:2234.
24. Zamai L, Mariani AR, Zauli G, at al. Kinetics of in vitro natural killer activity against K562 cells as detected by flow cytometry. Cytometry. 1998;32: 280.
25. + hematopoietic progenitors express low levels of CD4, the high affinity receptor for human immunodeficiency virus-type 1 (HIV-1). Blood. 1994;84:1896.
26. Strauss LC, Bowley SD, La Russa VF, Sharkis SS, Stuart RK, Civin CI. Antigen analysis of hematopoiesis: characterization of My-10 antigen expression by normal lymphohematopoietic progenitor cells. Exp Hematol. 1986;14:878.
27. Loken MR, Shan VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. I. Normal erythroid development. Blood. 1987;69: 255.
28. Zauli G, Catani L. Human megakaryocyte biology and pathophysiology. Crit Rev Oncol Hematol. 1995;21:135.
29. Koury MJ. Programmed cell death (apoptosis) in hematopoiesis. Exp Hematol. 1992;20:391.
30. Koller MR, Bradley MS, Palsson BO. Growth factor consumption and production in perfusion cultures of human bone marrow correlate with specific cell production. Exp Hematol. 1995;23:1275.
31. Terstappen LW, Buescher S, Nguyen M, Reading C. Differentiation and maturation of growth factor expanded human hematopoietic progenitors assessed by multidimensional flow cytometry. Leukemia. 1992;6:1001.
32. De Maria R, Zeuner A, Eramo A, et al. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature. 1999;401:489.
33. Perkins DL, Michaelson J, Marshak-Rothstein A. The lpr gene is associated with resistance to engraftment by lymphoid but not erythroid stem cells from normal mice. J Immunol. 1987;138: 466.
34. Oyaizu, N. Adachi Y, Hashimoto F, et al. Monocytes express Fas ligand upon CD4 cross-linking and induce CD4 T cell apoptosis. J Immunol. 1997;158:2456.
35. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med. 1999;189: 1343.
36. Katsikis PD, Garcia-Ojeda ME, Torres-Roca JF, et al. Interleukin-1 beta converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection: TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection. J Exp Med. 1997;186: 1365.
37. Sedger LM, Shows DM, Blanton RA, et al. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol. 1999;163:920.
38. Phillips TA, Ni J, Pan G, et al. TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege. J Immunol. 1999; 162:6053.
39. Gura T. How TRAIL kills cancer cells, but not normal cells. Science. 1997;277:768.
40. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science. 1997;276:111.
41. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818.
42. Sheikh MS, Burns TF, Huang Y, et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 1998;58:1593.
43. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 1999;59:734.
44. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155.
45. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157.
46. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate NF-kappaB. Immunity. 1997;7:821.
47. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 1999;59:2747.
48. Griffith TS, Rauch CT, Smolak PJ, et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol. 1999;162:2597.
49. Nagata S, Golstein P. The Fas death factor. Science. 1995;5:1449.
50. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997;326:1.
51. Iwai K, Miyawaki T, Takizawa T, et al. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood. 1994: 84:1201.